366-45-0

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
2-CHLORO-N-(2-FLUORO-4-METHYLPHENYL)ACETAMIDE is utilized as a key intermediate in the synthesis of potential new medications. Its unique structure allows it to interact with biological systems, potentially influencing physiological processes and offering a promising avenue for the treatment of various health conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-CHLORO-N-(2-FLUORO-4-METHYLPHENYL)ACETAMIDE is employed as a building block for designing and optimizing drug candidates. Its ability to modulate biological targets makes it a valuable tool for developing novel therapeutic agents with improved efficacy and selectivity.
Used in Chemical Synthesis:
2-CHLORO-N-(2-FLUORO-4-METHYLPHENYL)ACETAMIDE serves as a versatile reagent in chemical synthesis, enabling the creation of a wide range of compounds with diverse applications. Its unique functional groups facilitate various chemical reactions, contributing to the development of new materials and compounds with potential applications in various industries.
Used in Biochemical Studies:
In biochemical research, 2-CHLORO-N-(2-FLUORO-4-METHYLPHENYL)ACETAMIDE is used to investigate the interactions between small molecules and biological macromolecules. Its ability to modulate biological processes makes it a valuable probe for understanding the molecular mechanisms underlying various diseases and conditions.
Overall, 2-CHLORO-N-(2-FLUORO-4-METHYLPHENYL)ACETAMIDE is a multifaceted chemical compound with broad applications in pharmaceutical research, drug development, medicinal chemistry, chemical synthesis, and biochemical studies. Its unique structural features and potential to interact with biological systems make it a valuable asset for scientists and medical professionals seeking to advance our understanding of health and disease.

InChI:InChI=1/C9H9ClFNO/c1-6-2-3-8(7(11)4-6)12-9(13)5-10/h2-4H,5H2,1H3,(H,12,13)

Upstream product

• 446-34-4 2-fluoro-4-methyl-1-nitrobenzene 
• 452-80-2 2-fluoro-4-methylaniline 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 2377-28-8 N,N-diethyl-glycine-(2-fluoro-4-methyl-anilide) 

Relevant academic research and scientific papers

Synthesis, biological evaluation, and structure-activity relationships of new tubulin polymerization inhibitors based on 5-amino-1,2,4-triazole scaffold

Based on our previous research, thirty new 5-amino-1H-1,2,4-triazoles possessing 3,4,5-trimethoxyphenyl moiety were synthesized, and evaluated for antiproliferative activities. Among them, compounds IIa, IIIh, and IIIm demonstrated significant antiproliferative activities against a panel of tumor cell lines, and the promising compound IIIm dose-dependently caused G2/M phase arrest in HeLa cells. Furthermore, analogue IIa exhibited the most potent tubulin polymerization inhibitory activity with an IC50 value of 9.4 μM, and molecular modeling studies revealed that IIa formed stable interactions in the colchicine-binding site of tubulin, suggesting that 5-amino-1H-1,2,4-triazole scaffold has potential for further investigation to develop novel tubulin polymerization inhibitors with anticancer activity.

Synthesis and Biological Evaluation of Dithiobisacetamides as Novel Urease Inhibitors

Thirty-eight disulfides containing N-arylacetamide were designed and synthesized in an effort to develop novel urease inhibitors. Biological evaluation revealed that some of the synthetic compounds exhibited strong inhibitory potency against both cell-free urease and urease in intact cell with low cytotoxicity to mammalian cells even at concentration up to 250 μM. Of note, 2,2′-dithiobis(N-(2-fluorophenyl)acetamide) (d7), 2,2′-dithiobis(N-(3,5-difluorophenyl)acetamide) (d24), and 2,2′-dithiobis(N-(3-fluorophenyl)acetamide) (d8) were here identified as the most active inhibitors with IC50 of 0.074, 0.44, and 0.81 μM, showing 32- to 355-fold higher potency than the positive control acetohydroxamic acid. These disulfides were confirmed to bind urease without covalent modification of the cysteine residue and to inhibit urease reversibly with a mixed inhibition mechanism. They also showed very good anti-Helicobacter pylori activities with d8 showing a comparable potency to the clinical used drug amoxicillin. The impressive in vitro biological profile indicated their immense potential as therapeutic agents to tackle H. pylori caused infections.

Discovery of new indole-based 1,2,4-triazole derivatives as potent tubulin polymerization inhibitors with anticancer activity

Thirty-six novel indole-based 1,2,4-triazole derivatives were designed and synthesized through the molecular hybrid strategy. The bioassay results revealed that 9p displayed excellent antiproliferative efficacies in the nanomolar range against HeLa cells. Importantly, the compound exhibited no obvious cytotoxic activity (IC50 > 100 μM) toward HEK-293, a normal human embryonic kidney cell line. Mechanism analysis indicated that 9p significantly arrested the cell cycle at the G2/M phase and induced apoptosis in HeLa cells in a dose-dependent manner. Further evidence demonstrated that the promising compound effectively inhibited tubulin polymerization with an IC50 value of 8.3 μM, and molecular docking studies revealed that 9p well occupied the colchicine-site in tubulin. The present study highlights that indole-triazole hybrids might be used as a promising scaffold to develop novel tubulin polymerization inhibitors for cancer treatment.

Discovery and optimization of 3,4,5-trimethoxyphenyl substituted triazolylthioacetamides as potent tubulin polymerization inhibitors

Based on our previous research, three series of new triazolylthioacetamides possessing 3,4,5-trimethoxyphenyl moiety were synthesized, and evaluated for antiproliferative activities and inhibition of tubulin polymerization. The most promising compounds 8b and 8j demonstrated more significant antiproliferative activities against MCF-7, HeLa, and HT-29 cell lines than our lead compound 6. Moreover, analogues 8f, 8j, and 8o manifested more potent antiproliferative activities against HeLa cell line with IC50 values of 0.04, 0.05 and 0.16 μM, respectively, representing 100-, 82-, and 25-fold improvements of the activity compared to compound 6. Furthermore, the representative compound, 8j, was found to induce significant cell cycle arrest at the G2/M phase in HeLa cell lines via a concentration-dependent manner. Meanwhile, compound 8b exhibited the most potent tubulin polymerization inhibitory activity with an IC50 value of 5.9 μM, which was almost as active as that of CA-4 (IC50 = 4.2 μM). Additionally, molecular docking analysis suggested that 8b formed stable interactions in the colchicine-binding site of tubulin.

Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics

Small molecule choline kinase inhibitors having the following formula: are provided herein. Also provided herein are pharmaceutical compositions containing Formula I compounds, together with methods of treating cancer, methods of inhibiting choline kinase enzymatic activity, and methods of treating tumors by administering an effective amount of a Formula I compound.